Vernal keratoconjunctivitis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:26:59 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Vernal keratoconjunctivitis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study Comparing Tacrolimus and Ciclosporin Eye Drops for Children and Adults with Moderate to Severe Vernal Keratoconjunctivitis https://clinicaltrials.eu/trial/a-study-comparing-tacrolimus-and-ciclosporin-eye-drops-for-children-and-adults-with-moderate-to-severe-vernal-keratoconjunctivitis/ Wed, 29 Apr 2026 15:07:45 +0000 https://clinicaltrials.eu/trial/a-study-comparing-tacrolimus-and-ciclosporin-eye-drops-for-children-and-adults-with-moderate-to-severe-vernal-keratoconjunctivitis/ This study is looking at Vernal Keratoconjunctivitis, a condition that affects the eyes and causes symptoms like sensitivity to light, excessive tearing, itching, and mucus discharge. The study will compare two different eye drop treatments to see which one works better for people with moderate to severe forms of this condition. One treatment is T1695, which contains tacrolimus monohydrate and is given as an eye drop suspension twice a day. The other treatment is Verkazia, which contains ciclosporin and is given as an eye drop emulsion four times a day. The purpose of the study is to compare how well these two treatments work in reducing damage to the surface of the eye, specifically the clear front part of the eye called the cornea.

The study will involve children and teenagers between 4 and 18 years old who have moderate to severe symptoms and have experienced flare-ups of the condition in the past year. Participants will receive one of the two eye drop treatments for about six months. During this time, doctors will check how the eyes are responding to treatment by looking at changes in corneal damage, symptoms like itching and tearing, and overall eye health. The study will measure these changes at different time points, starting from the beginning of treatment through the end of the study period. Doctors will use special scales and measurements to track improvements in eye surface damage and will ask participants about their symptoms and quality of life.

Throughout the study, safety will be monitored by checking for any unwanted effects from the eye drops, measuring blood pressure and other vital signs, and doing blood tests to check kidney and liver function. For participants receiving T1695, blood samples will be taken to measure the amount of tacrolimus in the bloodstream. The study will also track whether participants need additional rescue medications and whether the condition comes back after treatment is stopped. The entire study will last several months and will help determine which treatment is more effective and safer for managing this eye condition in young people.

]]>